-
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study. J Am Acad Dermatol. 2024 Mar 28.
Gebauer K, Spelman L, Yamauchi PS, Bagel J, Nishandar T, Crane M, Kopeloff I, Kothekar M, Yao SL, Sofen HL. PMID: 38554938.
View in:
PubMed Mentions: Fields:
-
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials. Br J Dermatol. 2024 Jan 16.
Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A. PMID: 38226713.
View in:
PubMed Mentions: Fields:
-
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Clin Transl Sci. 2024 Jan; 17(1):e13682.
Mohamed MF, Qian Y, D'Cunha R, Sligh T, Ferris LK, Eldred A, Levy GF, Hao S, Gannu S, Rizzo DG, Liu W, Jazayeri S, Sofen H, Carcereri De Prati R. PMID: 38112262; PMCID: PMC10766045.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis. J Am Acad Dermatol. 2023 Dec 18.
Blauvelt A, Rich P, Sofen H, Strober B, Merola JF, Lebwohl M, Morita A, Szepietowski JC, Lambert J, Hippeli L, Colston E, Balagula E, Banerjee S, Thaçi D. PMID: 38122848.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. Immunotherapy. 2023 08; 15(11):787-797.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. PMID: 37150956.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study. J Am Acad Dermatol. 2023 08; 89(2):235-242.
Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, Chen Y, Rao N, Denis L, Gupta S. PMID: 37094653.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCTClinical Trials
-
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023 02 10; 188(2):198-207.
Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C. PMID: 36763857.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Mar; 57:101826.
Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. PMID: 36816342; PMCID: PMC9932343.
View in:
PubMed Mentions:
11
-
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023 01; 88(1):40-51.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. PMID: 36115523.
View in:
PubMed Mentions:
35 Fields:
Translation:
HumansCTClinical Trials
-
Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial. JAMA Dermatol. 2021 Nov 01; 157(11):1306-1315.
Harris KM, Smilek DE, Byron M, Lim N, Barry WT, McNamara J, Garcet S, Konrad RJ, Stengelin M, Bathala P, Korman NJ, Feldman SR, Boh EE, Barber K, Laumann AE, Helfrich YR, Krueger GG, Sofen H, Bissonnette R, Krueger JG. PMID: 34643650; PMCID: PMC8515260.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. J Eur Acad Dermatol Venereol. 2021 Dec; 35(12):2398-2408.
Warren RB, Lebwohl M, Sofen H, Piguet V, Augustin M, Brock F, Fierens F, Blauvelt A. PMID: 34192387; PMCID: PMC9290019.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCTClinical Trials
-
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2022 01; 86(1):77-85.
Stein Gold L, Papp K, Pariser D, Green L, Bhatia N, Sofen H, Albrecht L, Gooderham M, Chen M, Paris M, Wang Y, Callis Duffin K. PMID: 34343599.
View in:
PubMed Mentions:
10 Fields:
Translation:
HumansCTClinical Trials
-
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. Br J Dermatol. 2021 10; 185(4):840-842.
Van Voorhees AS, Stein Gold L, Lebwohl M, Strober B, Sofen H, Papp K, Bagel J, Zhang Z, Paris M, Wang Y. PMID: 33763874; PMCID: PMC8518877.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat. 2022 Jun; 33(4):2085-2093.
Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L. PMID: 33947295.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020 Jul; 83(1):96-103.
Van Voorhees AS, Stein Gold L, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y. PMID: 32032692.
View in:
PubMed Mentions:
21 Fields:
Translation:
HumansCTClinical Trials
-
Perspectives on Living with Chronic Spontaneous Urticaria: From Onset through Diagnosis and Disease Management in the US. Acta Derm Venereol. 2019 Nov 01; 99(12):1091-1098.
Goldstein S, Eftekhari S, Mitchell L, Winders TA, Kaufman L, Dudas D, Paknis B, Kavati A, Delwart V, Sofen HL. PMID: 31396637.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2019 Dec; 33(12):2305-2312.
Blauvelt A, Sofen H, Papp K, Gooderham M, Tyring S, Zhao Y, Lowry S, Mendelsohn A, Parno J, Reich K. PMID: 31407394; PMCID: PMC6899626.
View in:
PubMed Mentions:
16 Fields:
Translation:
Humans
-
Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor. J Eur Acad Dermatol Venereol. 2019 10; 33(10):e350-e352.
Gooderham M, Elewski BE, Pariser DM, Sofen H, Mendelsohn AM, Rozzo SJ, Li Q. PMID: 31033068; PMCID: PMC6850306.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol. 2019 10; 181(4):733-742.
Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Guttman-Yassky E. PMID: 30919407; PMCID: PMC6850605.
View in:
PubMed Mentions:
33 Fields:
Translation:
HumansCells
-
A reliability study using Network Oriented Research Assistant (NORA® ) examining the use of digital photographs in the assessment of psoriasis. Br J Dermatol. 2019 07; 181(1):214-215.
Jeong D, Aralis H, Bruhn KW, Cotliar J, Craft N, DeLuca IJ, Hamidi R, Nguyen K, Patel VA, Sofen H, Tan BH, David CV. PMID: 30703265.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp. J Dermatolog Treat. 2019 Dec; 30(8):775-783.
Wang Y, Coyne K, Sofen H, Santanello N, Currie B, Zhang Z, Nograles K. PMID: 30747550.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
A reliability study using Network-Oriented Research Assistant to evaluate the use of digital photographs in the assessment of atopic dermatitis. J Am Acad Dermatol. 2021 09; 85(3):725-726.
Hughes ME, Aralis H, Bruhn KW, Cotliar J, Craft N, DeLuca IJ, Hamidi R, Nguyen K, Patel M, Patel VA, Sofen H, Tan BH, David CV. PMID: 30703454.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. J Am Assoc Nurse Pract. 2018 Sep; 30(9):529-541.
Tofte SJ, Papp K, Sadick N, Bohnert K, Simpson E, Thaçi D, Bieber T, Blauvelt A, Sofen H, Gooderham M, Chen Z, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Ardeleanu M. PMID: 30211823.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansCTClinical Trials
-
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661.
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. PMID: 30097359.
View in:
PubMed Mentions:
200 Fields:
Translation:
HumansCTClinical Trials
-
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018 Aug; 79(2):266-276.e5.
Lebwohl M, Blauvelt A, Paul C, Sofen H, Weglowska J, Piguet V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M. PMID: 29660425.
View in:
PubMed Mentions:
40 Fields:
Translation:
HumansCTClinical Trials
-
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018 05; 78(5):863-871.e11.
Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, Owen R, Putnam W, Castro M, DeBusk K, Lin CY, Voulgari A, Yen K, Omachi TA. PMID: 29353026.
View in:
PubMed Mentions:
98 Fields:
Translation:
HumansCTClinical Trials
-
Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study. J Am Acad Dermatol. 2018 04; 78(4):793-795.
Casale TB, Win PH, Bernstein JA, Rosén K, Holden M, Iqbal A, Trzaskoma BL, Yang M, Antonova EN, Murphy T, Scarupa MD, Sofen H, Kaplan A. PMID: 29037993.
View in:
PubMed Mentions:
4 Fields:
Translation:
HumansCTClinical Trials
-
Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. J Eur Acad Dermatol Venereol. 2018 Jan; 32(1):68-72.
Paul C, Guenther L, Torii H, Sofen H, Burge R, Lin CY, Potts Bleakman A, Mallbris L, Poulin Y. PMID: 28881462.
View in:
PubMed Mentions:
9 Fields:
Translation:
HumansCTClinical Trials
-
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials. J Eur Acad Dermatol Venereol. 2017 Nov; 31(11):1867-1875.
Guenther L, Warren RB, Cather JC, Sofen H, Poulin Y, Lebwohl M, Terui T, Potts Bleakman A, Zhu B, Burge R, Reich K, van de Kerkhof P. PMID: 28573743.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. J Eur Acad Dermatol Venereol. 2017 Oct; 31(10):1693-1699.
Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S. PMID: 28602039; PMCID: PMC6084293.
View in:
PubMed Mentions:
8 Fields:
Translation:
HumansCTClinical Trials
-
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. Adv Ther. 2017 07; 34(7):1772.
Adsit S, Zaldivar ER, Sofen H, Dei-Cas I, Maldonado-García C, Peñaranda EO, Puig L, Meng X, Fox T, Guana A. PMID: 28589404; PMCID: PMC5504197.
View in:
PubMed Mentions: Fields:
-
Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017 Sep; 31(9):1483-1490.
Leonardi CL, Blauvelt A, Sofen HL, Gooderham M, Augustin M, Burge R, Zhu B, Reich K. PMID: 28294430.
View in:
PubMed Mentions:
8 Fields:
Translation:
HumansCTClinical Trials
-
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017 04 20; 376(16):1551-1560.
Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. PMID: 28423301.
View in:
PubMed Mentions:
180 Fields:
Translation:
HumansCTClinical Trials
-
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. Adv Ther. 2017 06; 34(6):1327-1339.
Adsit S, Zaldivar ER, Sofen H, Dei-Cas I, Maldonado-García C, Peñaranda EO, Puig L, Meng X, Fox T, Guana A. PMID: 28397079; PMCID: PMC5487875.
View in:
PubMed Mentions:
8 Fields:
Translation:
HumansCTClinical Trials
-
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017 Jun; 31(6):1004-1013.
Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. PMID: 28190255; PMCID: PMC5485049.
View in:
PubMed Mentions:
19 Fields:
Translation:
HumansCTClinical Trials
-
Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol. 2017 Jun; 31(6):1056-1063.
Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein JA. PMID: 27911016; PMCID: PMC6084322.
View in:
PubMed Mentions:
17 Fields:
Translation:
Humans
-
Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Treat. 2017 Aug; 28(5):384-389.
Korman NJ, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Nyirady J, Williams N, Mordin M, Tyring S. PMID: 27832717.
View in:
PubMed Mentions:
4 Fields:
Translation:
HumansCTClinical Trials
-
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017 Jun; 28(4):282-287.
Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, Goldblum O, Dennehy EB, Kerr L, Sofen H. PMID: 27759463.
View in:
PubMed Mentions:
10 Fields:
Translation:
HumansCTClinical Trials
-
Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2017 Feb; 31(2):323-332.
Griffiths CE, Vender R, Sofen H, Kircik L, Tan H, Rottinghaus ST, Bachinsky M, Mallbris L, Mamolo C. PMID: 27600367; PMCID: PMC5297866.
View in:
PubMed Mentions:
11 Fields:
Translation:
HumansCTClinical Trials
-
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016 Jan 02; 387(10013):40-52.
Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. PMID: 26454361.
View in:
PubMed Mentions:
157 Fields:
Translation:
HumansCTClinical Trials
-
A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015 Jul; 73(1):99-105.e1.
Sofen H, Gross KG, Goldberg LH, Sharata H, Hamilton TK, Egbert B, Lyons B, Hou J, Caro I. PMID: 25913533.
View in:
PubMed Mentions:
25 Fields:
Translation:
HumansCTClinical Trials
-
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2015; 172(5):1395-406.
Bissonnette R, Iversen L, Sofen H, Griffiths CE, Foley P, Romiti R, Bachinsky M, Rottinghaus ST, Tan H, Proulx J, Valdez H, Gupta P, Mallbris L, Wolk R. PMID: 25418186.
View in:
PubMed Mentions:
63 Fields:
Translation:
HumansCTClinical Trials
-
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015 Mar 09; 27(3):327-41.
Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ. PMID: 25759019; PMCID: PMC5675004.
View in:
PubMed Mentions:
180 Fields:
Translation:
HumansCells
-
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015 Feb; 172(2):484-93.
Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S, FEATURE Study Group. PMID: 25132411.
View in:
PubMed Mentions:
108 Fields:
Translation:
HumansCTClinical Trials
-
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014 Apr; 133(4):1032-40.
Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ, Wasfi Y, Wang Y, Szapary P, Krueger JG. PMID: 24679469.
View in:
PubMed Mentions:
96 Fields:
Translation:
HumansCellsCTClinical Trials
-
Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014 Feb; 170(2):398-407.
Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, Kerkmann U, Ghislain PD, Poulin Y, PHOENIX 1 investigators. PMID: 24117389.
View in:
PubMed Mentions:
32 Fields:
Translation:
HumansCTClinical Trials
-
Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. J Drugs Dermatol. 2013 Aug; 12(8):874-80.
Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB. PMID: 23986160.
View in:
PubMed Mentions:
10 Fields:
Translation:
HumansCTClinical Trials
-
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec; 27(12):1535-45.
Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB, PHOENIX 1 Investigators. PMID: 23279003.
View in:
PubMed Mentions:
51 Fields:
Translation:
HumansCTClinical Trials
-
Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab. J Drugs Dermatol. 2012 Dec; 11(12):1498-501.
Opel D, Economidi A, Chan D, Wasfi Y, Mistry S, Vergou T, Antoniou C, Sofen H. PMID: 23377523.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012 Aug 25; 380(9843):738-46.
Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. PMID: 22748702.
View in:
PubMed Mentions:
81 Fields:
Translation:
HumansCTClinical Trials
-
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J Am Acad Dermatol. 2012 Oct; 67(4):642-50.
Gottlieb AB, Kalb RE, Blauvelt A, Heffernan MP, Sofen HL, Ferris LK, Kerdel FA, Calabro S, Wang J, Kerkmann U, Chevrier M. PMID: 22153792.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis. Cutis. 2011 Oct; 88(4):201-7.
Hudson CP, Kempers S, Menter A, Papp K, Smith S, Sofen H, Colón LE, Johnson LA, Gottschalk R. PMID: 22106730.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. J Drugs Dermatol. 2011 Aug; 10(8):885-92.
Sofen H, Hudson CP, Cook-Bolden FE, Preston N, Colón LE, Colón LE, Caveney SW, Gottschalk RW. PMID: 21818510.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis. Cutis. 2011 Jul; 88(1):46-51.
Menter A, Sofen H, Smith S, Papp K, Kempers S, Hudson CP, Colón LE, Johnson LA, Gottschalk R. PMID: 21877508.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. J Eur Acad Dermatol Venereol. 2011 Jul; 25(7):851-7.
Guenther L, Han C, Szapary P, Schenkel B, Poulin Y, Bourcier M, Ortonne JP, Sofen HL. PMID: 21521375.
View in:
PubMed Mentions:
19 Fields:
Translation:
Humans
-
Noninvasive genomic detection of melanoma. Br J Dermatol. 2011 Apr; 164(4):797-806.
Wachsman W, Morhenn V, Palmer T, Walls L, Hata T, Zalla J, Scheinberg R, Sofen H, Mraz S, Gross K, Rabinovitz H, Polsky D, Chang S. PMID: 21294715; PMCID: PMC3118279.
View in:
PubMed Mentions:
28 Fields:
Translation:
Humans
-
Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses. J Clin Aesthet Dermatol. 2009 Apr; 2(4):20-8.
Del Rosso JQ, Sofen H, Leshin B, Meng T, Kulp J, Levy S. PMID: 20729935; PMCID: PMC2923947.
View in:
PubMed Mentions:
5